These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12426926)

  • 1. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in prescribed drug doses after market introduction.
    Heerdink ER; Urquhart J; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):447-53. PubMed ID: 12426928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vioxx fears prompt call for user fee evaluation.
    Frantz S
    Nat Rev Drug Discov; 2005 Mar; 4(3):179. PubMed ID: 15770775
    [No Abstract]   [Full Text] [Related]  

  • 6. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug effects: new information about an old problem.
    Miller CA
    Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 9. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 10. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 11. US importer and distributor requirements.
    Donawa M
    Med Device Technol; 2005 Jun; 16(5):25-7. PubMed ID: 15984543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Policy issues concerning antimicrobials: problems with the regulatory process governing their introduction.
    Simon HJ
    Hosp Formul; 1985 May; 20(5):629-31, 634. PubMed ID: 10271104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 15. Making medicines safer--the need for an independent drug safety board.
    Wood AJ; Stein CM; Woosley R
    N Engl J Med; 1998 Dec; 339(25):1851-4. PubMed ID: 9854125
    [No Abstract]   [Full Text] [Related]  

  • 16. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-market approval surveillance: a call for a more integrated and comprehensive approach.
    Mehran R; Leon MB; Feigal DA; Jefferys D; Simons M; Chronos N; Fogarty TJ; Kuntz RE; Baim DS; Kaplan AV
    Circulation; 2004 Jun; 109(25):3073-7. PubMed ID: 15226222
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating drugs after their approval for clinical use.
    Ray WA; Griffin MR; Avorn J
    N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk management of marketed drugs: FDA and the interface with the practice of medicine.
    Uhl K; Honig P
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):205-8. PubMed ID: 11501332
    [No Abstract]   [Full Text] [Related]  

  • 20. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.